Instruction 1(b)

FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

**OMB APPROVAL** 3235-0287 OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Ho Carole					2. Issuer Name and Ticker or Trading Symbol NGM BIOPHARMACEUTICALS INC NGM ]							eck all applic	or		10% Ov	vner	
(Last) (First) (Middle) C/O NGM BIOPHARMACEUTICALS, INC. 333 OYSTER POINT BOULEVARD					3. Date of Earliest Transaction (Month/Day/Year) 04/05/2024							Officer below)	(give title		Other (s below)	specify	
					4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street) SOUTH FRANCE		A	94080										iled by One iled by More		•		
FRANCI	ISCO			_ R	ule 1	10b	5-1(c)	) Transac	tion Ind	ication							
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												
		Tab	le I - Non-Der	ivativ	e Sec	curit	ties Ac	quired, Di	sposed o	f, or Bei	neficial	y Owned					
1. Title of Security (Instr. 3)  2. Transa Date (Month/D					Execution Date,		tion Date	Code (Ins				Beneficia	s ally following	Form	: Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code V			Amount	(A) or (D)	Price	Transact (Instr. 3 a	ion(s)			(IIISU. 4)			
		-	Table II - Deriv (e.g.,					uired, Dis			•	Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)		10. Ownership Form:	Beneficial Ownership (Instr. 4)	
	Security		(Month/Day/Year)	8)		Acq (A) ( Disp of (I	urities uired or oosed O) (Instr.	(	ear)	Derivative	Security	(Instr. 5)	Beneficiall Owned Following Reported Transactio	ly	Direct (D) or Indirect (I) (Instr. 4)		
	Security		(Month/Day/Year)	8)	v	Acq (A) ( Disp of (I	urities uired or oosed O) (Instr.	Date Exercisable	Expiration Date	Derivative	Security		Beneficiall Owned Following Reported Transactio	ly	Direct (D) or Indirect		
Stock Option (Right to Buy)	\$3.69 <sup>(1)(2)</sup>	04/05/2024	(Month/Day/Year)		v	Acq (A) o Disp of (I 3, 4	urities uired or oosed O) (Instr. and 5)	Date	Expiration	Derivative (Instr. 3 an	Amount or Number of		Beneficiall Owned Following Reported Transactio	ly	Direct (D) or Indirect		
Option (Right to		04/05/2024 04/05/2024	(Month/Day/Year)	Code	v	Acq (A) o Disp of (I 3, 4	urities uired or oosed D) (Instr. and 5)	Date Exercisable	Expiration Date	Derivative (Instr. 3 and Title	Amount or Number of Shares	(Instr. 5)	Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	Direct (D) or Indirect (I) (Instr. 4)		
Option (Right to Buy)  Stock Option (Right to	\$3.69(1)(2)		(Month/Day/Year)	Code	v	Acq (A) o Disp of (I 3, 4	urities uired or or oosed o) (Instr. and 5)	Date Exercisable	Expiration Date	Derivative (Instr. 3 and Instr. 3 and Instr. 3 and Instr. 3 and Instruction   Title   Common Stock	Amount or Number of Shares	(lnstr. 5)	Beneficiall Owned Following Reported Transactio (Instr. 4)	ly	Direct (D) or Indirect (I) (Instr. 4)		

## **Explanation of Responses:**

1. This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger entered into by and among the Issuer, Atlas Neon Parent, Inc. ("Parent") and Atlas Neon Merger Sub, Inc., a wholly-owned subsidiary of Parent ("Purchaser"), dated as of February 25, 2024 ("Merger Agreement"), pursuant to which the Purchaser completed a tender offer for the shares of common stock of the Issuer and thereafter merged with and into the Issuer effective as of April 5, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement and Purchaser's offer to purchase, the shares of common stock were tendered to Purchaser in consideration for a per share price of \$1.55 in cash, subject to applicable tax withholding and without interest (the "Offer Price").

2. Pursuant to the Merger Agreement, as of the Effective Time, the vesting of each outstanding unvested Stock Option that had a per share exercise price that was less than the Offer Price (an "In-the-Money Option") was accelerated, any applicable retention period for options that were repriced ended, and each outstanding In-the-Money Option (both vested and unvested) was canceled and the holder of such canceled Stock Option was entitled to receive an amount in cash, without interest and less any withholding of taxes, equal to the product of (i) the excess of the Offer Price over the applicable exercise price per share subject to such Stock Option multiplied by (ii) the total number of shares subject to such Stock Option that was not an In-the-Money Option (whether vested or unvested) was canceled as of the Effective Time for no consideration.

/s/ Valerie Pierce, Attorney-in-

04/05/2024

**Fact** 

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>\*</sup> If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

<sup>\*\*</sup> Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).